Study Title: A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Green, Kimberly, at greekm@musc.edu.Study Coordinator, Mendiola, Hannah, at mendiola@musc.edu.Trial opened at the following institutions: Medical University of South Carolina